Live Breaking News & Updates on Clinical laboratory fees
Stay updated with breaking news from Clinical laboratory fees. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
4DMT Molecular Therapeutics Inc. is looking ahead to phase III as positive data continue to roll out for gene therapy candidate 4D-150 in wet age-related macular degeneration (AMD), with the results from the phase II portion of the phase I/II Prism trial showing the single-shot treatment significantly reduced the need for chronic anti-VEGF injections.
Tens of thousands of people with Jewish ancestry who are more likely to carry a genetic fault that can increase the risk of developing some cancers will receive genetic testing through a new prog
Beckman Coulter Diagnostics, a leader in clinical diagnostics, will reveal its latest innovation, the DxC 500 AU Chemistry Analyzer, at Medlab Middle East in Dubai from 5-8 February 2024. Click to read more...
Biogen Inc.’s problematic trip with Aduhelm (aducanumab-avwa) for Alzheimer’s disease at last came to an end as the company, probably surprising few on Wall Street, said it’s quitting sales and development of the amyloid-beta directed antibody. The drug won accelerated approval by the U.S. FDA in July 2021.
Despite Vertex Pharmaceuticals Inc.’s mostly positive phase III study results of a non-opioid for treating moderate to severe acute pain, the data for a key secondary endpoint show VX-548 is not as effective as Vicodin (hydrocodone, Abbvie Inc.). Neither of two randomized, double-blind, placebo-controlled, pivotal studies, one treating patients after abdominoplasty surgery and one after bunionectomy surgery, met the key secondary endpoint of VX-548 being superior to hydrocodone bitartrate/acetaminophen in patients’ pain levels.
Shares of Corbus Pharmaceuticals Inc. (NASDAQ:CRBP) doubled on opening Jan. 26 and ended the day up a whopping 249% as investors got a look at data from a first-in-human study testing next-generation Nectin-4-targeted antibody-drug conjugate (ADC) CRB-701. Licensed from CSPC Pharmaceutical Group for $7.5 million up front in February 2023, CRB-701 has IND clearance from the U.S. FDA, and Corbus plans to start its own clinical testing in the first quarter of 2024.
The hearing has returned for the first person who has received gene therapy for treating genetic hearing loss in the U.S. Initial results from Akouos Inc.’s phase I/II study showed that within 30 days of receiving AK-OTOF-101, pharmacologic hearing was restored to an 11-year-old who had profound hearing loss from birth.
THE University of Santo Tomas (UST) and Hualien Tzu Chi Hospital and Medical Center in Taiwan have joined forces to conduct a clinical study on telomeres.
Dxcover Ltd. initiated three pivotal trials to measure the efficacy of its liquid biopsy platform for early detection of brain, colorectal and lung cancers. The company hopes the trials will provide the evidence needed to gain regulatory approval and begin commercial operations of its diagnostic technology in Europe and the U.S.